DOI QR코드

DOI QR Code

Macrophage migration inhibitory factor: a potential therapeutic target for rheumatoid arthritis

  • Kim, Kyoung-Woon (Convergent Research Consortium for Immunologic Disease, College of Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea) ;
  • Kim, Hae-Rim (Division of Rheumatology, Department of Internal Medicine, Research Institute of Medical Science, Konkuk University School of Medicine)
  • Received : 2016.04.07
  • Accepted : 2016.04.26
  • Published : 2016.07.01

Abstract

Macrophage migration inhibitory factor (MIF) is originally identified in the culture medium of activated T lymphocytes as a soluble factor that inhibits the random migration of macrophages. MIF is now recognized as a multipotent cytokine involved in the regulation of immune and inf lammatory responses. In rheumatoid arthritis (RA), MIF promotes inf lammatory responses by inducing proinflammatory cytokines and tissue-degrading molecules, promoting the proliferation and survival of synovial fibroblasts, stimulating neutrophil chemotaxis, and regulating angiogenesis and osteoclast differentiation. Expression of MIF in synovial tissue and synovial fluid levels of MIF are elevated in RA patients. Specifically, MIF levels correlate with RA disease activity and high levels are associated with bone erosion. In animal models of RA, the genetic and therapeutic inhibition of MIF has been shown to control inflammation and bone destruction. Based on the role of MIF in RA pathogenesis, small molecular inhibitors targeting it or its receptor pathways could provide a new therapeutic option for RA patients.

Keywords

Acknowledgement

Supported by : National Research Foundation of Korea (NRF)

References

  1. Montecucco F, Mach F. Common inflammatory mediators orchestrate pathophysiological processes in rheumatoid arthritis and atherosclerosis. Rheumatology (Oxford) 2009;48:11-22. https://doi.org/10.1093/rheumatology/kep705
  2. Brennan FM, McInnes IB. Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest 2008;118:3537-3545. https://doi.org/10.1172/JCI36389
  3. Burmester GR, Feist E, Dorner T. Emerging cell and cytokine targets in rheumatoid arthritis. Nat Rev Rheumatol 2014;10:77-88. https://doi.org/10.1038/nrrheum.2013.168
  4. David JR. Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction. Proc Natl Acad Sci U S A 1966;56:72-77. https://doi.org/10.1073/pnas.56.1.72
  5. Bernhagen J, Calandra T, Mitchell RA, et al. MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature 1993;365:756-759. https://doi.org/10.1038/365756a0
  6. Sun HW, Swope M, Cinquina C, et al. The subunit structure of human macrophage migration inhibitory factor: evidence for a trimer. Protein Eng 1996;9:631-635. https://doi.org/10.1093/protein/9.8.631
  7. Calandra T, Bernhagen J, Mitchell RA, Bucala R. The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J Exp Med 1994;179:1895-1902. https://doi.org/10.1084/jem.179.6.1895
  8. Bacher M, Metz CN, Calandra T, et al. An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. Proc Natl Acad Sci U S A 1996;93:7849-7854. https://doi.org/10.1073/pnas.93.15.7849
  9. Rossi AG, Haslett C, Hirani N, et al. Human circulating eosinophils secrete macrophage migration inhibitory factor (MIF): potential role in asthma. J Clin Invest 1998;101:2869-2874. https://doi.org/10.1172/JCI1524
  10. Daryadel A, Grifone RF, Simon HU, Yousefi S. Apoptotic neutrophils release macrophage migration inhibitory factor upon stimulation with tumor necrosis factor-alpha. J Biol Chem 2006;281:27653-27661. https://doi.org/10.1074/jbc.M604051200
  11. Imamura K, Nishihira J, Suzuki M, et al. Identification and immunohistochemical localization of macrophage migration inhibitory factor in human kidney. Biochem Mol Biol Int 1996;40:1233-1242.
  12. Shimizu T. Role of macrophage migration inhibitory factor (MIF) in the skin. J Dermatol Sci 2005;37:65-73. https://doi.org/10.1016/j.jdermsci.2004.08.007
  13. Nishihira J, Koyama Y, Mizue Y. Identification of macrophage migration inhibitory factor (MIF) in human vascular endothelial cells and its induction by lipopolysaccharide. Cytokine 1998;10:199-205. https://doi.org/10.1006/cyto.1997.0276
  14. Verschuren L, Lindeman JH, van Bockel JH, Abdul-Hussien H, Kooistra T, Kleemann R. Up-regulation and coexpression of MIF and matrix metalloproteinases in human abdominal aortic aneurysms. Antioxid Redox Signal 2005;7:1195-1202. https://doi.org/10.1089/ars.2005.7.1195
  15. Bernhagen J, Krohn R, Lue H, et al. MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat Med 2007;13:587-596. https://doi.org/10.1038/nm1567
  16. Mitchell RA, Metz CN, Peng T, Bucala R. Sustained mitogen-activated protein kinase (MAPK) and cytoplasmic phospholipase A2 activation by macrophage migration inhibitory factor (MIF): regulatory role in cell proliferation and glucocorticoid action. J Biol Chem 1999;274:18100-18106. https://doi.org/10.1074/jbc.274.25.18100
  17. Calandra T, Roger T. Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol 2003;3:791-800. https://doi.org/10.1038/nri1200
  18. Calandra T, Bernhagen J, Metz CN, et al. MIF as a glucocorticoid-induced modulator of cytokine production. Nature 1995;377:68-71. https://doi.org/10.1038/377068a0
  19. Mitchell RA, Liao H, Chesney J, et al. Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: regulatory role in the innate immune response. Proc Natl Acad Sci U S A 2002;99:345-350. https://doi.org/10.1073/pnas.012511599
  20. de Jong YP, Abadia-Molina AC, Satoskar AR, et al. Development of chronic colitis is dependent on the cytokine MIF. Nat Immunol 2001;2:1061-1066. https://doi.org/10.1038/ni720
  21. Niino M, Ogata A, Kikuchi S, Tashiro K, Nishihira J. Macrophage migration inhibitory factor in the cerebrospinal fluid of patients with conventional and optic-spinal forms of multiple sclerosis and neuro-Behcet's disease. J Neurol Sci 2000;179(Suppl 1-2):127-131. https://doi.org/10.1016/S0022-510X(00)00397-X
  22. Denkinger CM, Denkinger M, Kort JJ, Metz C, Forsthuber TG. In vivo blockade of macrophage migration inhibitory factor ameliorates acute experimental autoimmune encephalomyelitis by impairing the homing of encephalitogenic T cells to the central nervous system. J Immunol 2003;170:1274-1282. https://doi.org/10.4049/jimmunol.170.3.1274
  23. Foote A, Briganti EM, Kipen Y, Santos L, Leech M, Morand EF. Macrophage migration inhibitory factor in systemic lupus erythematosus. J Rheumatol 2004;31:268-273.
  24. Sreih A, Ezzeddine R, Leng L, et al. Dual effect of the macrophage migration inhibitory factor gene on the development and severity of human systemic lupus erythematosus. Arthritis Rheum 2011;63:3942-3951. https://doi.org/10.1002/art.30624
  25. Boyce NW, Tipping PG, Holdsworth SR. Lymphokine (MIF) production by glomerular T-lymphocytes in experimental glomerulonephritis. Kidney Int 1986;30:673-677. https://doi.org/10.1038/ki.1986.239
  26. Lan HY, Yang N, Nikolic-Paterson DJ, et al. Expression of macrophage migration inhibitory factor in human glomerulonephritis. Kidney Int 2000;57:499-509. https://doi.org/10.1046/j.1523-1755.2000.00869.x
  27. Steinhoff M, Meinhardt A, Steinhoff A, Gemsa D, Bucala R, Bacher M. Evidence for a role of macrophage migration inhibitory factor in psoriatic skin disease. Br J Dermatol 1999;141:1061-1066. https://doi.org/10.1046/j.1365-2133.1999.03206.x
  28. Shimizu T, Nishihira J, Mizue Y, et al. High macrophage migration inhibitory factor (MIF) serum levels associated with extended psoriasis. J Invest Dermatol 2001;116:989-990. https://doi.org/10.1046/j.0022-202x.2001.01366.x
  29. Meazza C, Travaglino P, Pignatti P, et al. Macrophage migration inhibitory factor in patients with juvenile idiopathic arthritis. Arthritis Rheum 2002;46:232-237. https://doi.org/10.1002/1529-0131(200201)46:1<232::AID-ART10059>3.0.CO;2-B
  30. Wakabayashi K, Otsuka K, Sato M, et al. Elevated serum levels of macrophage migration inhibitory factor and their significant correlation with rheumatoid vasculitis disease activity. Mod Rheumatol 2012;22:59-65. https://doi.org/10.3109/s10165-011-0466-z
  31. Kim HR, Park MK, Cho ML, et al. Induction of macrophage migration inhibitory factor in ConA-stimulated rheumatoid arthritis synovial fibroblasts through the P38 map kinase-dependent signaling pathway. Korean J Intern Med 2010;25:317-326. https://doi.org/10.3904/kjim.2010.25.3.317
  32. Llamas-Covarrubias MA, Valle Y, Navarro-Hernandez RE, et al. Serum levels of macrophage migration inhibitory factor are associated with rheumatoid arthritis course. Rheumatol Int 2012;32:2307-2311. https://doi.org/10.1007/s00296-011-1951-6
  33. Onodera S, Tanji H, Suzuki K, et al. High expression of macrophage migration inhibitory factor in the synovial tissues of rheumatoid joints. Cytokine 1999;11:163-167. https://doi.org/10.1006/cyto.1998.0402
  34. Kim HR, Park MK, Cho ML, et al. Macrophage migration inhibitory factor upregulates angiogenic factors and correlates with clinical measures in rheumatoid arthritis. J Rheumatol 2007;34:927-936.
  35. Onodera S, Kaneda K, Mizue Y, Koyama Y, Fujinaga M, Nishihira J. Macrophage migration inhibitory factor up-regulates expression of matrix metalloproteinases in synovial fibroblasts of rheumatoid arthritis. J Biol Chem 2000;275:444-450. https://doi.org/10.1074/jbc.275.1.444
  36. Onodera S, Nishihira J, Iwabuchi K, et al. Macrophage migration inhibitory factor up-regulates matrix metalloproteinase-9 and -13 in rat osteoblasts. Relevance to intracellular signaling pathways. J Biol Chem 2002;277:7865-7874. https://doi.org/10.1074/jbc.M106020200
  37. Vincenti MP, White LA, Schroen DJ, Benbow U, Brinckerhoff CE. Regulating expression of the gene for matrix metalloproteinase-1 (collagenase): mechanisms that control enzyme activity, transcription, and mRNA stability. Crit Rev Eukaryot Gene Expr 1996;6:391-411. https://doi.org/10.1615/CritRevEukarGeneExpr.v6.i4.40
  38. Chauchereau A, Georgiakaki M, Perrin-Wolff M, Milgrom E, Loosfelt H. JAB1 interacts with both the progesterone receptor and SRC-1. J Biol Chem 2000;275:8540-8548. https://doi.org/10.1074/jbc.275.12.8540
  39. Eichbaum QG, Iyer R, Raveh DP, Mathieu C, Ezekowitz RA. Restriction of interferon gamma responsiveness and basal expression of the myeloid human Fc gamma R1b gene is mediated by a functional PU.1 site and a transcription initiator consensus. J Exp Med 1994;179:1985-1996. https://doi.org/10.1084/jem.179.6.1985
  40. Santos L, Hall P, Metz C, Bucala R, Morand EF. Role of macrophage migration inhibitory factor (MIF) in murine antigen-induced arthritis: interaction with glucocorticoids. Clin Exp Immunol 2001;123:309-314. https://doi.org/10.1046/j.1365-2249.2001.01423.x
  41. Leech M, Lacey D, Xue JR, et al. Regulation of p53 by macrophage migration inhibitory factor in inflammatory arthritis. Arthritis Rheum 2003;48:1881-1889. https://doi.org/10.1002/art.11165
  42. Lacey D, Sampey A, Mitchell R, et al. Control of fibroblast-like synoviocyte proliferation by macrophage migration inhibitory factor. Arthritis Rheum 2003;48:103-109. https://doi.org/10.1002/art.10733
  43. Roger T, David J, Glauser MP, Calandra T. MIF regulates innate immune responses through modulation of Tolllike receptor 4. Nature 2001;414:920-924. https://doi.org/10.1038/414920a
  44. Onodera S, Suzuki K, Matsuno T, Kaneda K, Takagi M, Nishihira J. Macrophage migration inhibitory factor induces phagocytosis of foreign particles by macrophages in autocrine and paracrine fashion. Immunology 1997;92:131-137. https://doi.org/10.1046/j.1365-2567.1997.00311.x
  45. Leech M, Metz C, Hall P, et al. Macrophage migration inhibitory factor in rheumatoid arthritis: evidence of proinflammatory function and regulation by glucocorticoids. Arthritis Rheum 1999;42:1601-1608. https://doi.org/10.1002/1529-0131(199908)42:8<1601::AID-ANR6>3.0.CO;2-B
  46. Toh ML, Aeberli D, Lacey D, et al. Regulation of IL-1 and TNF receptor expression and function by endogenous macrophage migration inhibitory factor. J Immunol 2006;177:4818-4825. https://doi.org/10.4049/jimmunol.177.7.4818
  47. Herenius MM, Oliveira AS, Wijbrandts CA, Gerlag DM, Tak PP, Lebre MC. Anti-TNF therapy reduces serum levels of chemerin in rheumatoid arthritis: a new mechanism by which anti-TNF might reduce inflammation. PLoS One 2013;8:e57802. https://doi.org/10.1371/journal.pone.0057802
  48. Loppnow H, Libby P. Adult human vascular endothelial cells express the IL6 gene differentially in response to LPS or IL1. Cell Immunol 1989;122:493-503. https://doi.org/10.1016/0008-8749(89)90095-6
  49. O'Shea F, Salonen D, Inman R. The challenge of early diagnosis in ankylosing spondylitis. J Rheumatol 2007;34:5-7.
  50. Kim HR, Kim KW, Jung HG, et al. Macrophage migration inhibitory factor enhances osteoclastogenesis through upregulation of RANKL expression from fibroblast-like synoviocytes in patients with rheumatoid arthritis. Arthritis Res Ther 2011;13:R43. https://doi.org/10.1186/ar3279
  51. Liu R, Xu N, Wang X, et al. Influence of MIF, CD40, and CD226 polymorphisms on risk of rheumatoid arthritis. Mol Biol Rep 2012;39:6915-6922. https://doi.org/10.1007/s11033-012-1518-y
  52. Llamas-Covarrubias MA, Valle Y, Bucala R, et al. Macrophage migration inhibitory factor (MIF): genetic evidence for participation in early onset and early stage rheumatoid arthritis. Cytokine 2013;61:759-765. https://doi.org/10.1016/j.cyto.2012.12.032
  53. Bucala R. Signal transduction: a most interesting factor. Nature 2000;408:146-147. https://doi.org/10.1038/35041654
  54. Leng L, Metz CN, Fang Y, et al. MIF signal transduction initiated by binding to CD74. J Exp Med 2003;197:1467-1476. https://doi.org/10.1084/jem.20030286
  55. Firestein GS, Manning AM. Signal transduction and transcription factors in rheumatic disease. Arthritis Rheum 1999;42:609-621. https://doi.org/10.1002/1529-0131(199904)42:4<609::AID-ANR3>3.0.CO;2-I
  56. Kyriakis JM, Avruch J. Protein kinase cascades activated by stress and inflammatory cytokines. Bioessays 1996;18:567-577. https://doi.org/10.1002/bies.950180708
  57. Santos LL, Lacey D, Yang Y, Leech M, Morand EF. Activation of synovial cell p38 MAP kinase by macrophage migration inhibitory factor. J Rheumatol 2004;31:1038-1043.
  58. Ren Y, Chan HM, Li Z, et al. Upregulation of macrophage migration inhibitory factor contributes to induced N-Myc expression by the activation of ERK signaling pathway and increased expression of interleukin-8 and VEGF in neuroblastoma. Oncogene 2004;23:4146-4154. https://doi.org/10.1038/sj.onc.1207490
  59. Sun B, Nishihira J, Suzuki M, et al. Induction of macrophage migration inhibitory factor by lysophosphatidic acid: relevance to tumor growth and angiogenesis. Int J Mol Med 2003;12:633-641.
  60. Watanabe H, Shimizu T, Nishihira J, et al. Ultraviolet A-induced production of matrix metalloproteinase-1 is mediated by macrophage migration inhibitory factor (MIF) in human dermal fibroblasts. J Biol Chem 2004;279:1676-1683. https://doi.org/10.1074/jbc.M303650200
  61. Amin MA, Volpert OV, Woods JM, Kumar P, Harlow LA, Koch AE. Migration inhibitory factor mediates angiogenesis via mitogen-activated protein kinase and phosphatidylinositol kinase. Circ Res 2003;93:321-329. https://doi.org/10.1161/01.RES.0000087641.56024.DA
  62. Kleemann R, Grell M, Mischke R, Zimmermann G, Bernhagen J. Receptor binding and cellular uptake studies of macrophage migration inhibitory factor (MIF): use of biologically active labeled MIF derivatives. J Interferon Cytokine Res 2002;22:351-363. https://doi.org/10.1089/107999002753675785
  63. Bernhagen J, Mitchell RA, Calandra T, Voelter W, Cerami A, Bucala R. Purification, bioactivity, and secondary structure analysis of mouse and human macrophage migration inhibitory factor (MIF). Biochemistry 1994;33:14144-14155. https://doi.org/10.1021/bi00251a025
  64. Stavitsky AB, Xianli J. In vitro and in vivo regulation by macrophage migration inhibitory factor (MIF) of expression of MHC-II, costimulatory, adhesion, receptor, and cytokine molecules. Cell Immunol 2002;217:95-104. https://doi.org/10.1016/S0008-8749(02)00516-6
  65. Mikulowska A, Metz CN, Bucala R, Holmdahl R. Macrophage migration inhibitory factor is involved in the pathogenesis of collagen type II-induced arthritis in mice. J Immunol 1997;158:5514-5517.
  66. Leech M, Metz C, Santos L, et al. Involvement of macrophage migration inhibitory factor in the evolution of rat adjuvant arthritis. Arthritis Rheum 1998;41:910-917. https://doi.org/10.1002/1529-0131(199805)41:5<910::AID-ART19>3.0.CO;2-E
  67. Leech M, Metz C, Bucala R, Morand EF. Regulation of macrophage migration inhibitory factor by endogenous glucocorticoids in rat adjuvant-induced arthritis. Arthritis Rheum 2000;43:827-833. https://doi.org/10.1002/1529-0131(200004)43:4<827::AID-ANR13>3.0.CO;2-K
  68. Ichiyama H, Onodera S, Nishihira J, et al. Inhibition of joint inflammation and destruction induced by anti-type II collagen antibody/lipopolysaccharide (LPS)-induced arthritis in mice due to deletion of macrophage migration inhibitory factor (MIF). Cytokine 2004;26:187-194. https://doi.org/10.1016/j.cyto.2004.02.007
  69. Gregory JL, Leech MT, David JR, Yang YH, Dacumos A, Hickey MJ. Reduced leukocyte-endothelial cell interactions in the inflamed microcirculation of macrophage migration inhibitory factor-deficient mice. Arthritis Rheum 2004;50:3023-3034. https://doi.org/10.1002/art.20470
  70. Bresnihan B, Alvaro-Gracia JM, Cobby M, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998;41:2196-2204. https://doi.org/10.1002/1529-0131(199812)41:12<2196::AID-ART15>3.0.CO;2-2
  71. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial. Ann Intern Med 1999;130:478-486. https://doi.org/10.7326/0003-4819-130-6-199903160-00004
  72. Targan SR, Hanauer SB, van Deventer SJ, et al. A shortterm study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997;337:1029-1035. https://doi.org/10.1056/NEJM199710093371502
  73. Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999;354:1932-1939. https://doi.org/10.1016/S0140-6736(99)05246-0

Cited by

  1. Altered Macrophage and Dendritic Cell Response in Mif −/− Mice Reveals a Role of Mif for Inflammatory-Th1 Response in Type 1 Diabetes vol.2016, pp.None, 2016, https://doi.org/10.1155/2016/7053963
  2. Urinary Macrophage Migration Inhibitory Factor as a Noninvasive Biomarker in Pediatric Henoch-Schönlein Purpura Nephritis : vol.23, pp.5, 2016, https://doi.org/10.1097/rhu.0000000000000570
  3. The Role of High-Mobility Group Box-1 and Its Crosstalk with Microbiome in Rheumatoid Arthritis vol.2017, pp.None, 2016, https://doi.org/10.1155/2017/5230374
  4. CXCR4 signaling in macrophages contributes to periodontal mechanical hypersensitivity in Porphyromonas gingivalis -induced periodontitis in mice vol.13, pp.None, 2016, https://doi.org/10.1177/1744806916689269
  5. Histamine and Histamine H4 Receptor Promotes Osteoclastogenesis in Rheumatoid Arthritis vol.7, pp.None, 2017, https://doi.org/10.1038/s41598-017-01101-y
  6. Macrophage migration inhibitory factor (MIF) promotes rat airway muscle cell proliferation and migration mediated by ERK1/2 and FAK signaling : MIF promotes ASMC proliferation and migration vol.42, pp.1, 2016, https://doi.org/10.1002/cbin.10863
  7. Roles of macrophage migration inhibitory factor in Guillain-Barré syndrome and experimental autoimmune neuritis: beneficial or harmful? vol.22, pp.7, 2018, https://doi.org/10.1080/14728222.2018.1484109
  8. Macrophage migration inhibitory factor (MIF) inhibitor, Z-590 suppresses cartilage destruction in adjuvant-induced arthritis via inhibition of macrophage inflammatory activation vol.40, pp.2, 2018, https://doi.org/10.1080/08923973.2018.1424896
  9. Novel Target Sites for Drug Screening: A Special Reference to Cancer, Rheumatoid Arthritis and Parkinson’s Disease vol.14, pp.2, 2019, https://doi.org/10.2174/1574362413666180320112810
  10. Quercetin, a Plant Polyphenol, Has Potential for the Prevention of Bone Destruction in Rheumatoid Arthritis vol.22, pp.2, 2019, https://doi.org/10.1089/jmf.2018.4259
  11. Macrophage migration inhibitory factor (MIF) inhibitor 4‐IPP suppresses osteoclast formation and promotes osteoblast differentiation through the inhibition of the NF‐κB signaling p vol.33, pp.6, 2016, https://doi.org/10.1096/fj.201802364rr
  12. Toll-like receptor 7 regulates osteoclastogenesis in rheumatoid arthritis vol.166, pp.3, 2016, https://doi.org/10.1093/jb/mvz033
  13. Genetic and molecular determinants of prostate cancer among Iranian patients: An update vol.57, pp.1, 2016, https://doi.org/10.1080/10408363.2019.1657061
  14. Glioblastoma Myeloid-Derived Suppressor Cell Subsets Express Differential Macrophage Migration Inhibitory Factor Receptor Profiles That Can Be Targeted to Reduce Immune Suppression vol.11, pp.None, 2016, https://doi.org/10.3389/fimmu.2020.01191
  15. Correlations of MIF polymorphism and serum levels of MIF with glucocorticoid sensitivity of sudden sensorineural hearing loss vol.48, pp.4, 2016, https://doi.org/10.1177/0300060519893870
  16. Molecular and Cellular Heterogeneity in Rheumatoid Arthritis: Mechanisms and Clinical Implications vol.12, pp.None, 2021, https://doi.org/10.3389/fimmu.2021.790122
  17. Anti‑inflammatory activity of different isolated sites of Chloranthus serratus in complete Freund's adjuvant‑induced arthritic rats vol.22, pp.2, 2016, https://doi.org/10.3892/etm.2021.10280
  18. The Novel Role of MIF in the Secretion of IL-25, IL-31, and IL-33 from PBMC of Patients with Rheumatoid Arthritis vol.26, pp.16, 2016, https://doi.org/10.3390/molecules26164968
  19. The interplay between fibroblast‐like synovial and vascular endothelial cells leads to angiogenesis via the sphingosine‐1‐phosphate‐induced RhoA‐F‐Actin and Ras vol.35, pp.9, 2016, https://doi.org/10.1002/ptr.7211
  20. Canonical (CD74/CD44) and Non-Canonical (CXCR2, 4 and 7) MIF Receptors Are Differentially Expressed in Rheumatoid Arthritis Patients Evaluated by DAS28-ESR vol.11, pp.1, 2022, https://doi.org/10.3390/jcm11010120